Skip to content
NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP

Guardant Health, Inc. GH

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$982.0M
▲ 32.9% YoY
$-416.3M
$-233.1M
In brief

What this company does

Guardant Health, Inc. provides tests that span all stages of cancer care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For early cancer detection, it offers the Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease. It performs clinical, research-use-only, and investigation-use-only tests in laboratories located in Redwood City, California, and Long Island City, New York, with its Redwood City, San Diego and Palo Alto, California laboratories also operating as centers for research and technology development. As of December 31, 2025, it had 2,506 employees, 2,490 of which are full-time, with approximately 2,278 in the U.S. and the remainder in Asia, Europe and Canada.

Written from the business description in GUARDANT HEALTH, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.

Growth
USD 982.0M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 982.0 · Net income -416.3
400.0M800.0M-250.0M-500.0M201720182019202020212022202320242025
Compound annual growth
+29.8%
+27.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +27.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−42 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -44.5% · Net -42.4%
-50%-100%-150%201720182019202020212022202320242025
ROE
FY2024 · ROE -4584.5%
-2000%-4000%201720182019202020212022202320242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -233.1
-200M201720182019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks -212.1
-200M-400M2017201820192020202320242025

Total assetsUSD 2.0B
EquityUSD -99.3M
CashUSD 378.2M
Gross debtUSD 1.5B
Net debtUSD 1.1B
Current ratio4.84×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B1.00.70.60.40.40.30.20.10.0
Operating income $B−0.4−0.4−0.6−0.5−0.4−0.3−0.1−0.1−0.1
EBITDA $B−0.4−0.4−0.5−0.5−0.4−0.2−0.1−0.1−0.1
Income tax $B−0.00.00.00.00.00.0−0.00.00.0
Net income $B−0.4−0.4−0.5−0.7−0.4−0.2−0.1−0.1−0.1
Free cash flow $B−0.2−0.3−0.3−0.4−0.3−0.1−0.1−0.1−0.1
EPS, diluted $−3.32−3.56−4.28−6.41−4.00−2.60−0.84−2.80−7.07
Dividend / sh $·········
Payout %·········
ROE %·−4584.5−438.1−185.7−39.6·−11.8−21.5−27.0
Shares out B0.130.120.120.100.100.100.090.09·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 58 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image